Logo image
Back
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (vol 42, pg 751, 2019)
Journal article   Open access   Peer reviewed

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs (vol 42, pg 751, 2019)

Subrata Ghosh, Lianne S. Gensler, Zijiang Yang, Chris Gasink, Soumya D. Chakravarty, Kamyar Farahi, Paraneedharan Ramachandran, Elyssa Ott and Bruce E. Strober
Drug safety, v 42(6), pp 809-809
01 Jun 2019
DOI: https://doi.org/10.1007/s40264-019-00816-3
PMID: 31012051
url
https://doi.org/10.1007/s40264-019-00816-3View
Published, Version of Record (VoR) Open CC BY-NC V4.0

Abstract

Life Sciences & Biomedicine Pharmacology & Pharmacy Public, Environmental & Occupational Health Science & Technology Toxicology
1 Correction to: Drug Safety https://doi.org/10.1007/s40264-019-00797-3 In the original publication of this article, the following correction should be noted in Table 5. The 95% CI for serious infections in the Ustekinumab −MTX group under PsA should read 0.8–3.5 and not 0.8–3.5.5.

Metrics

5 Record Views
6 citations in Web of Science
8 citations in Scopus

Details

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Pharmacology & Pharmacy
Public, Environmental & Occupational Health
Toxicology
Logo image